Industry Research Reports

Home > Reports > Medical Devices & Consumables > Global Lysosomal Storage Disorders Market Research Report 2023

Global Lysosomal Storage Disorders Market Research Report 2023

Industry: Medical Devices & Consumables

Published: 2023-09-03

Pages: 94 Pages

Report ld: 1502062

Description
Table of Contents
Table of Figures
PDF Download

Description
Table of Contents
Table of Figures
PDF Download

Lysosomal storage diseases or disorders (LSDs) are rare genetic conditions that cause a buildup of toxic materials in your body's cells. People with LSDs lack certain enzymes or a substance that helps the enzyme work (enzyme activator or modifier).

According to QYResearch’s new survey, global Lysosomal Storage Disorders market is projected to reach US$ 2230.4 million in 2029, increasing from US$ 1280 million in 2022, with the CAGR of 8.2% during the period of 2023 to 2029.

The global lysosomal storage disorders (LSD) market refers to the market for therapeutic treatments, diagnostic tools, and supportive care for various lysosomal storage disorders. Lysosomal storage disorders are a group of rare genetic disorders characterized by the accumulation of specific substances within the lysosomes of cells. These disorders result from deficiencies of enzymes or transporters responsible for breaking down these substances.

Lysosomal storage disorders can affect various organs and systems in the body, leading to a wide range of symptoms and complications. Some common lysosomal storage disorders include Gaucher disease, Fabry disease, Pompe disease, Niemann-Pick disease, and mucopolysaccharidoses.

The market for lysosomal storage disorders is driven by several factors. Firstly, increased awareness and advancements in diagnostic techniques have led to improved detection and diagnosis of these disorders. This has resulted in a growing patient population and a higher demand for therapeutic interventions.

Secondly, advancements in treatment options, including enzyme replacement therapies, substrate reduction therapies, gene therapies, and chaperone therapies, have significantly improved patient outcomes. These innovative therapies aim to restore or replace the deficient enzymes, reduce the accumulation of substrates, or correct the underlying genetic defect.

Thirdly, supportive care and management play a crucial role in the overall treatment of lysosomal storage disorders. This includes symptomatic relief, physical therapy, nutrition management, genetic counseling, and psychological support. The market for supportive care products and services is also an important aspect of the overall lysosomal storage disorders market.

The market for lysosomal storage disorders is segmented based on the type of disorder, treatment modality, end-user, and geography. The types of disorders may include Gaucher disease, Fabry disease, Pompe disease, Niemann-Pick disease, mucopolysaccharidoses, and others. Treatment modalities may include enzyme replacement therapies, substrate reduction therapies, gene therapies, chaperone therapies, and others. End-users of these therapies and products include hospitals, specialty clinics, research centers, and homecare settings.

Geographically, the market is divided into regions such as North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America and Europe hold a significant market share due to the presence of established healthcare infrastructure, high awareness, and supportive reimbursement policies. The Asia Pacific region is expected to witness rapid market growth due to improving healthcare infrastructure, increasing awareness, and growing investments in research and development.

Key players in the global lysosomal storage disorders market include pharmaceutical companies, biotechnology companies, and research organizations. These companies focus on research and development activities, clinical trials, and collaborations to bring innovative therapies and diagnostic tools to the market. They also work towards improving access to these therapies, especially in regions with limited healthcare infrastructure or resources.

In summary, the global lysosomal storage disorders market is driven by factors such as increased awareness, advancements in diagnostic techniques, and innovative treatment options. The market encompasses therapeutic interventions, diagnostic tools, and supportive care products and services. With ongoing research and development efforts, the market is expected to grow as more effective and targeted therapies become available, improving the quality of life for patients with lysosomal storage disorders.The global lysosomal storage disorders (LSD) market refers to the market for therapeutic treatments, diagnostic tools, and supportive care for various lysosomal storage disorders. Lysosomal storage disorders are a group of rare genetic disorders characterized by the accumulation of specific substances within the lysosomes of cells. These disorders result from deficiencies of enzymes or transporters responsible for breaking down these substances.

Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Lysosomal Storage Disorders market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.

By Company
Astellas Pharma
Astrazeneca
Actelion
Eli Lilly and Company
Merck & Co
Novo Nordisk
Amicus Therapeutics
Pfizer
Sanofi
BioMarin Pharmaceutical Inc.
Raptor Pharmaceuticals
Protalix Biotherapeutics Inc

Segment by Type
Enzyme Replacement Therapy
Stem Cell Therapy
Substrate Reduction Therapy
Chaperone Therapy
Others

Segment by Application
Hospital
Clinics
Stem Cell Transplant Centre
Research Institutes
Others

By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

The Lysosomal Storage Disorders report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies' Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source

 1 Report Overview
    1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global Lysosomal Storage Disorders Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
        1.2.2 Enzyme Replacement Therapy
        1.2.3 Stem Cell Therapy
        1.2.4 Substrate Reduction Therapy
        1.2.5 Chaperone Therapy
        1.2.6 Others
    1.3 Market by Application
        1.3.1 Global Lysosomal Storage Disorders Market Growth by Application: 2018 VS 2022 VS 2029
        1.3.2 Hospital
        1.3.3 Clinics
        1.3.4 Stem Cell Transplant Centre
        1.3.5 Research Institutes
        1.3.6 Others
    1.4 Study Objectives
    1.5 Years Considered
    1.6 Years Considered

 2 Global Growth Trends
    2.1 Global Lysosomal Storage Disorders Market Perspective (2018-2029)
    2.2 Lysosomal Storage Disorders Growth Trends by Region
        2.2.1 Global Lysosomal Storage Disorders Market Size by Region: 2018 VS 2022 VS 2029
        2.2.2 Lysosomal Storage Disorders Historic Market Size by Region (2018-2023)
        2.2.3 Lysosomal Storage Disorders Forecasted Market Size by Region (2024-2029)
    2.3 Lysosomal Storage Disorders Market Dynamics
        2.3.1 Lysosomal Storage Disorders Industry Trends
        2.3.2 Lysosomal Storage Disorders Market Drivers
        2.3.3 Lysosomal Storage Disorders Market Challenges
        2.3.4 Lysosomal Storage Disorders Market Restraints

 3 Competition Landscape by Key Players
    3.1 Global Top Lysosomal Storage Disorders Players by Revenue
        3.1.1 Global Top Lysosomal Storage Disorders Players by Revenue (2018-2023)
        3.1.2 Global Lysosomal Storage Disorders Revenue Market Share by Players (2018-2023)
    3.2 Global Lysosomal Storage Disorders Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    3.3 Players Covered: Ranking by Lysosomal Storage Disorders Revenue
    3.4 Global Lysosomal Storage Disorders Market Concentration Ratio
        3.4.1 Global Lysosomal Storage Disorders Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by Lysosomal Storage Disorders Revenue in 2022
    3.5 Lysosomal Storage Disorders Key Players Head office and Area Served
    3.6 Key Players Lysosomal Storage Disorders Product Solution and Service
    3.7 Date of Enter into Lysosomal Storage Disorders Market
    3.8 Mergers & Acquisitions, Expansion Plans

 4 Lysosomal Storage Disorders Breakdown Data by Type
    4.1 Global Lysosomal Storage Disorders Historic Market Size by Type (2018-2023)
    4.2 Global Lysosomal Storage Disorders Forecasted Market Size by Type (2024-2029)

 5 Lysosomal Storage Disorders Breakdown Data by Application
    5.1 Global Lysosomal Storage Disorders Historic Market Size by Application (2018-2023)
    5.2 Global Lysosomal Storage Disorders Forecasted Market Size by Application (2024-2029)

 6 North America
    6.1 North America Lysosomal Storage Disorders Market Size (2018-2029)
    6.2 North America Lysosomal Storage Disorders Market Growth Rate by Country: 2018 VS 2022 VS 2029
    6.3 North America Lysosomal Storage Disorders Market Size by Country (2018-2023)
    6.4 North America Lysosomal Storage Disorders Market Size by Country (2024-2029)
    6.5 United States
    6.6 Canada

 7 Europe
    7.1 Europe Lysosomal Storage Disorders Market Size (2018-2029)
    7.2 Europe Lysosomal Storage Disorders Market Growth Rate by Country: 2018 VS 2022 VS 2029
    7.3 Europe Lysosomal Storage Disorders Market Size by Country (2018-2023)
    7.4 Europe Lysosomal Storage Disorders Market Size by Country (2024-2029)
    7.5 Germany
    7.6 France
    7.7 U.K.
    7.8 Italy
    7.9 Russia
    7.10 Nordic Countries

 8 Asia-Pacific
    8.1 Asia-Pacific Lysosomal Storage Disorders Market Size (2018-2029)
    8.2 Asia-Pacific Lysosomal Storage Disorders Market Growth Rate by Region: 2018 VS 2022 VS 2029
    8.3 Asia-Pacific Lysosomal Storage Disorders Market Size by Region (2018-2023)
    8.4 Asia-Pacific Lysosomal Storage Disorders Market Size by Region (2024-2029)
    8.5 China
    8.6 Japan
    8.7 South Korea
    8.8 Southeast Asia
    8.9 India
    8.10 Australia

 9 Latin America
    9.1 Latin America Lysosomal Storage Disorders Market Size (2018-2029)
    9.2 Latin America Lysosomal Storage Disorders Market Growth Rate by Country: 2018 VS 2022 VS 2029
    9.3 Latin America Lysosomal Storage Disorders Market Size by Country (2018-2023)
    9.4 Latin America Lysosomal Storage Disorders Market Size by Country (2024-2029)
    9.5 Mexico
    9.6 Brazil

 10 Middle East & Africa
    10.1 Middle East & Africa Lysosomal Storage Disorders Market Size (2018-2029)
    10.2 Middle East & Africa Lysosomal Storage Disorders Market Growth Rate by Country: 2018 VS 2022 VS 2029
    10.3 Middle East & Africa Lysosomal Storage Disorders Market Size by Country (2018-2023)
    10.4 Middle East & Africa Lysosomal Storage Disorders Market Size by Country (2024-2029)
    10.5 Turkey
    10.6 Saudi Arabia
    10.7 UAE

 11 Key Players Profiles
    11.1 Astellas Pharma
        11.1.1 Astellas Pharma Company Detail
        11.1.2 Astellas Pharma Business Overview
        11.1.3 Astellas Pharma Lysosomal Storage Disorders Introduction
        11.1.4 Astellas Pharma Revenue in Lysosomal Storage Disorders Business (2018-2023)
        11.1.5 Astellas Pharma Recent Development
    11.2 Astrazeneca
        11.2.1 Astrazeneca Company Detail
        11.2.2 Astrazeneca Business Overview
        11.2.3 Astrazeneca Lysosomal Storage Disorders Introduction
        11.2.4 Astrazeneca Revenue in Lysosomal Storage Disorders Business (2018-2023)
        11.2.5 Astrazeneca Recent Development
    11.3 Actelion
        11.3.1 Actelion Company Detail
        11.3.2 Actelion Business Overview
        11.3.3 Actelion Lysosomal Storage Disorders Introduction
        11.3.4 Actelion Revenue in Lysosomal Storage Disorders Business (2018-2023)
        11.3.5 Actelion Recent Development
    11.4 Eli Lilly and Company
        11.4.1 Eli Lilly and Company Company Detail
        11.4.2 Eli Lilly and Company Business Overview
        11.4.3 Eli Lilly and Company Lysosomal Storage Disorders Introduction
        11.4.4 Eli Lilly and Company Revenue in Lysosomal Storage Disorders Business (2018-2023)
        11.4.5 Eli Lilly and Company Recent Development
    11.5 Merck & Co
        11.5.1 Merck & Co Company Detail
        11.5.2 Merck & Co Business Overview
        11.5.3 Merck & Co Lysosomal Storage Disorders Introduction
        11.5.4 Merck & Co Revenue in Lysosomal Storage Disorders Business (2018-2023)
        11.5.5 Merck & Co Recent Development
    11.6 Novo Nordisk
        11.6.1 Novo Nordisk Company Detail
        11.6.2 Novo Nordisk Business Overview
        11.6.3 Novo Nordisk Lysosomal Storage Disorders Introduction
        11.6.4 Novo Nordisk Revenue in Lysosomal Storage Disorders Business (2018-2023)
        11.6.5 Novo Nordisk Recent Development
    11.7 Amicus Therapeutics
        11.7.1 Amicus Therapeutics Company Detail
        11.7.2 Amicus Therapeutics Business Overview
        11.7.3 Amicus Therapeutics Lysosomal Storage Disorders Introduction
        11.7.4 Amicus Therapeutics Revenue in Lysosomal Storage Disorders Business (2018-2023)
        11.7.5 Amicus Therapeutics Recent Development
    11.8 Pfizer
        11.8.1 Pfizer Company Detail
        11.8.2 Pfizer Business Overview
        11.8.3 Pfizer Lysosomal Storage Disorders Introduction
        11.8.4 Pfizer Revenue in Lysosomal Storage Disorders Business (2018-2023)
        11.8.5 Pfizer Recent Development
    11.9 Sanofi
        11.9.1 Sanofi Company Detail
        11.9.2 Sanofi Business Overview
        11.9.3 Sanofi Lysosomal Storage Disorders Introduction
        11.9.4 Sanofi Revenue in Lysosomal Storage Disorders Business (2018-2023)
        11.9.5 Sanofi Recent Development
    11.10 BioMarin Pharmaceutical Inc.
        11.10.1 BioMarin Pharmaceutical Inc. Company Detail
        11.10.2 BioMarin Pharmaceutical Inc. Business Overview
        11.10.3 BioMarin Pharmaceutical Inc. Lysosomal Storage Disorders Introduction
        11.10.4 BioMarin Pharmaceutical Inc. Revenue in Lysosomal Storage Disorders Business (2018-2023)
        11.10.5 BioMarin Pharmaceutical Inc. Recent Development
    11.11 Raptor Pharmaceuticals
        11.11.1 Raptor Pharmaceuticals Company Detail
        11.11.2 Raptor Pharmaceuticals Business Overview
        11.11.3 Raptor Pharmaceuticals Lysosomal Storage Disorders Introduction
        11.11.4 Raptor Pharmaceuticals Revenue in Lysosomal Storage Disorders Business (2018-2023)
        11.11.5 Raptor Pharmaceuticals Recent Development
    11.12 Protalix Biotherapeutics Inc
        11.12.1 Protalix Biotherapeutics Inc Company Detail
        11.12.2 Protalix Biotherapeutics Inc Business Overview
        11.12.3 Protalix Biotherapeutics Inc Lysosomal Storage Disorders Introduction
        11.12.4 Protalix Biotherapeutics Inc Revenue in Lysosomal Storage Disorders Business (2018-2023)
        11.12.5 Protalix Biotherapeutics Inc Recent Development

 12 Analyst's Viewpoints/Conclusions

 13 Appendix
    13.1 Research Methodology
        13.1.1 Methodology/Research Approach
        13.1.2 Data Source
    13.2 Disclaimer

List of Tables
    Table 1. Global Lysosomal Storage Disorders Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029
    Table 2. Key Players of Enzyme Replacement Therapy
    Table 3. Key Players of Stem Cell Therapy
    Table 4. Key Players of Substrate Reduction Therapy
    Table 5. Key Players of Chaperone Therapy
    Table 6. Key Players of Others
    Table 7. Global Lysosomal Storage Disorders Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029
    Table 8. Global Lysosomal Storage Disorders Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
    Table 9. Global Lysosomal Storage Disorders Market Size by Region (2018-2023) & (US$ Million)
    Table 10. Global Lysosomal Storage Disorders Market Share by Region (2018-2023)
    Table 11. Global Lysosomal Storage Disorders Forecasted Market Size by Region (2024-2029) & (US$ Million)
    Table 12. Global Lysosomal Storage Disorders Market Share by Region (2024-2029)
    Table 13. Lysosomal Storage Disorders Market Trends
    Table 14. Lysosomal Storage Disorders Market Drivers
    Table 15. Lysosomal Storage Disorders Market Challenges
    Table 16. Lysosomal Storage Disorders Market Restraints
    Table 17. Global Lysosomal Storage Disorders Revenue by Players (2018-2023) & (US$ Million)
    Table 18. Global Lysosomal Storage Disorders Market Share by Players (2018-2023)
    Table 19. Global Top Lysosomal Storage Disorders Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Lysosomal Storage Disorders as of 2022)
    Table 20. Ranking of Global Top Lysosomal Storage Disorders Companies by Revenue (US$ Million) in 2022
    Table 21. Global 5 Largest Players Market Share by Lysosomal Storage Disorders Revenue (CR5 and HHI) & (2018-2023)
    Table 22. Key Players Headquarters and Area Served
    Table 23. Key Players Lysosomal Storage Disorders Product Solution and Service
    Table 24. Date of Enter into Lysosomal Storage Disorders Market
    Table 25. Mergers & Acquisitions, Expansion Plans
    Table 26. Global Lysosomal Storage Disorders Market Size by Type (2018-2023) & (US$ Million)
    Table 27. Global Lysosomal Storage Disorders Revenue Market Share by Type (2018-2023)
    Table 28. Global Lysosomal Storage Disorders Forecasted Market Size by Type (2024-2029) & (US$ Million)
    Table 29. Global Lysosomal Storage Disorders Revenue Market Share by Type (2024-2029)
    Table 30. Global Lysosomal Storage Disorders Market Size by Application (2018-2023) & (US$ Million)
    Table 31. Global Lysosomal Storage Disorders Revenue Market Share by Application (2018-2023)
    Table 32. Global Lysosomal Storage Disorders Forecasted Market Size by Application (2024-2029) & (US$ Million)
    Table 33. Global Lysosomal Storage Disorders Revenue Market Share by Application (2024-2029)
    Table 34. North America Lysosomal Storage Disorders Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
    Table 35. North America Lysosomal Storage Disorders Market Size by Country (2018-2023) & (US$ Million)
    Table 36. North America Lysosomal Storage Disorders Market Size by Country (2024-2029) & (US$ Million)
    Table 37. Europe Lysosomal Storage Disorders Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
    Table 38. Europe Lysosomal Storage Disorders Market Size by Country (2018-2023) & (US$ Million)
    Table 39. Europe Lysosomal Storage Disorders Market Size by Country (2024-2029) & (US$ Million)
    Table 40. Asia-Pacific Lysosomal Storage Disorders Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029
    Table 41. Asia-Pacific Lysosomal Storage Disorders Market Size by Region (2018-2023) & (US$ Million)
    Table 42. Asia-Pacific Lysosomal Storage Disorders Market Size by Region (2024-2029) & (US$ Million)
    Table 43. Latin America Lysosomal Storage Disorders Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
    Table 44. Latin America Lysosomal Storage Disorders Market Size by Country (2018-2023) & (US$ Million)
    Table 45. Latin America Lysosomal Storage Disorders Market Size by Country (2024-2029) & (US$ Million)
    Table 46. Middle East & Africa Lysosomal Storage Disorders Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
    Table 47. Middle East & Africa Lysosomal Storage Disorders Market Size by Country (2018-2023) & (US$ Million)
    Table 48. Middle East & Africa Lysosomal Storage Disorders Market Size by Country (2024-2029) & (US$ Million)
    Table 49. Astellas Pharma Company Detail
    Table 50. Astellas Pharma Business Overview
    Table 51. Astellas Pharma Lysosomal Storage Disorders Product
    Table 52. Astellas Pharma Revenue in Lysosomal Storage Disorders Business (2018-2023) & (US$ Million)
    Table 53. Astellas Pharma Recent Development
    Table 54. Astrazeneca Company Detail
    Table 55. Astrazeneca Business Overview
    Table 56. Astrazeneca Lysosomal Storage Disorders Product
    Table 57. Astrazeneca Revenue in Lysosomal Storage Disorders Business (2018-2023) & (US$ Million)
    Table 58. Astrazeneca Recent Development
    Table 59. Actelion Company Detail
    Table 60. Actelion Business Overview
    Table 61. Actelion Lysosomal Storage Disorders Product
    Table 62. Actelion Revenue in Lysosomal Storage Disorders Business (2018-2023) & (US$ Million)
    Table 63. Actelion Recent Development
    Table 64. Eli Lilly and Company Company Detail
    Table 65. Eli Lilly and Company Business Overview
    Table 66. Eli Lilly and Company Lysosomal Storage Disorders Product
    Table 67. Eli Lilly and Company Revenue in Lysosomal Storage Disorders Business (2018-2023) & (US$ Million)
    Table 68. Eli Lilly and Company Recent Development
    Table 69. Merck & Co Company Detail
    Table 70. Merck & Co Business Overview
    Table 71. Merck & Co Lysosomal Storage Disorders Product
    Table 72. Merck & Co Revenue in Lysosomal Storage Disorders Business (2018-2023) & (US$ Million)
    Table 73. Merck & Co Recent Development
    Table 74. Novo Nordisk Company Detail
    Table 75. Novo Nordisk Business Overview
    Table 76. Novo Nordisk Lysosomal Storage Disorders Product
    Table 77. Novo Nordisk Revenue in Lysosomal Storage Disorders Business (2018-2023) & (US$ Million)
    Table 78. Novo Nordisk Recent Development
    Table 79. Amicus Therapeutics Company Detail
    Table 80. Amicus Therapeutics Business Overview
    Table 81. Amicus Therapeutics Lysosomal Storage Disorders Product
    Table 82. Amicus Therapeutics Revenue in Lysosomal Storage Disorders Business (2018-2023) & (US$ Million)
    Table 83. Amicus Therapeutics Recent Development
    Table 84. Pfizer Company Detail
    Table 85. Pfizer Business Overview
    Table 86. Pfizer Lysosomal Storage Disorders Product
    Table 87. Pfizer Revenue in Lysosomal Storage Disorders Business (2018-2023) & (US$ Million)
    Table 88. Pfizer Recent Development
    Table 89. Sanofi Company Detail
    Table 90. Sanofi Business Overview
    Table 91. Sanofi Lysosomal Storage Disorders Product
    Table 92. Sanofi Revenue in Lysosomal Storage Disorders Business (2018-2023) & (US$ Million)
    Table 93. Sanofi Recent Development
    Table 94. BioMarin Pharmaceutical Inc. Company Detail
    Table 95. BioMarin Pharmaceutical Inc. Business Overview
    Table 96. BioMarin Pharmaceutical Inc. Lysosomal Storage Disorders Product
    Table 97. BioMarin Pharmaceutical Inc. Revenue in Lysosomal Storage Disorders Business (2018-2023) & (US$ Million)
    Table 98. BioMarin Pharmaceutical Inc. Recent Development
    Table 99. Raptor Pharmaceuticals Company Detail
    Table 100. Raptor Pharmaceuticals Business Overview
    Table 101. Raptor Pharmaceuticals Lysosomal Storage Disorders Product
    Table 102. Raptor Pharmaceuticals Revenue in Lysosomal Storage Disorders Business (2018-2023) & (US$ Million)
    Table 103. Raptor Pharmaceuticals Recent Development
    Table 104. Protalix Biotherapeutics Inc Company Detail
    Table 105. Protalix Biotherapeutics Inc Business Overview
    Table 106. Protalix Biotherapeutics Inc Lysosomal Storage Disorders Product
    Table 107. Protalix Biotherapeutics Inc Revenue in Lysosomal Storage Disorders Business (2018-2023) & (US$ Million)
    Table 108. Protalix Biotherapeutics Inc Recent Development
    Table 109. Research Programs/Design for This Report
    Table 110. Key Data Information from Secondary Sources
    Table 111. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Lysosomal Storage Disorders Market Size Comparison by Type (2023-2029) & (US$ Million)
    Figure 2. Global Lysosomal Storage Disorders Market Share by Type: 2022 VS 2029
    Figure 3. Enzyme Replacement Therapy Features
    Figure 4. Stem Cell Therapy Features
    Figure 5. Substrate Reduction Therapy Features
    Figure 6. Chaperone Therapy Features
    Figure 7. Others Features
    Figure 8. Global Lysosomal Storage Disorders Market Size Comparison by Application (2023-2029) & (US$ Million)
    Figure 9. Global Lysosomal Storage Disorders Market Share by Application: 2022 VS 2029
    Figure 10. Hospital Case Studies
    Figure 11. Clinics Case Studies
    Figure 12. Stem Cell Transplant Centre Case Studies
    Figure 13. Research Institutes Case Studies
    Figure 14. Others Case Studies
    Figure 15. Lysosomal Storage Disorders Report Years Considered
    Figure 16. Global Lysosomal Storage Disorders Market Size (US$ Million), Year-over-Year: 2018-2029
    Figure 17. Global Lysosomal Storage Disorders Market Size, (US$ Million), 2018 VS 2022 VS 2029
    Figure 18. Global Lysosomal Storage Disorders Market Share by Region: 2022 VS 2029
    Figure 19. Global Lysosomal Storage Disorders Market Share by Players in 2022
    Figure 20. Global Top Lysosomal Storage Disorders Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Lysosomal Storage Disorders as of 2022)
    Figure 21. The Top 10 and 5 Players Market Share by Lysosomal Storage Disorders Revenue in 2022
    Figure 22. North America Lysosomal Storage Disorders Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 23. North America Lysosomal Storage Disorders Market Share by Country (2018-2029)
    Figure 24. United States Lysosomal Storage Disorders Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 25. Canada Lysosomal Storage Disorders Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 26. Europe Lysosomal Storage Disorders Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 27. Europe Lysosomal Storage Disorders Market Share by Country (2018-2029)
    Figure 28. Germany Lysosomal Storage Disorders Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 29. France Lysosomal Storage Disorders Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 30. U.K. Lysosomal Storage Disorders Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 31. Italy Lysosomal Storage Disorders Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 32. Russia Lysosomal Storage Disorders Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 33. Nordic Countries Lysosomal Storage Disorders Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 34. Asia-Pacific Lysosomal Storage Disorders Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 35. Asia-Pacific Lysosomal Storage Disorders Market Share by Region (2018-2029)
    Figure 36. China Lysosomal Storage Disorders Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 37. Japan Lysosomal Storage Disorders Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 38. South Korea Lysosomal Storage Disorders Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 39. Southeast Asia Lysosomal Storage Disorders Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 40. India Lysosomal Storage Disorders Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 41. Australia Lysosomal Storage Disorders Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 42. Latin America Lysosomal Storage Disorders Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 43. Latin America Lysosomal Storage Disorders Market Share by Country (2018-2029)
    Figure 44. Mexico Lysosomal Storage Disorders Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 45. Brazil Lysosomal Storage Disorders Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 46. Middle East & Africa Lysosomal Storage Disorders Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 47. Middle East & Africa Lysosomal Storage Disorders Market Share by Country (2018-2029)
    Figure 48. Turkey Lysosomal Storage Disorders Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 49. Saudi Arabia Lysosomal Storage Disorders Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 50. Astellas Pharma Revenue Growth Rate in Lysosomal Storage Disorders Business (2018-2023)
    Figure 51. Astrazeneca Revenue Growth Rate in Lysosomal Storage Disorders Business (2018-2023)
    Figure 52. Actelion Revenue Growth Rate in Lysosomal Storage Disorders Business (2018-2023)
    Figure 53. Eli Lilly and Company Revenue Growth Rate in Lysosomal Storage Disorders Business (2018-2023)
    Figure 54. Merck & Co Revenue Growth Rate in Lysosomal Storage Disorders Business (2018-2023)
    Figure 55. Novo Nordisk Revenue Growth Rate in Lysosomal Storage Disorders Business (2018-2023)
    Figure 56. Amicus Therapeutics Revenue Growth Rate in Lysosomal Storage Disorders Business (2018-2023)
    Figure 57. Pfizer Revenue Growth Rate in Lysosomal Storage Disorders Business (2018-2023)
    Figure 58. Sanofi Revenue Growth Rate in Lysosomal Storage Disorders Business (2018-2023)
    Figure 59. BioMarin Pharmaceutical Inc. Revenue Growth Rate in Lysosomal Storage Disorders Business (2018-2023)
    Figure 60. Raptor Pharmaceuticals Revenue Growth Rate in Lysosomal Storage Disorders Business (2018-2023)
    Figure 61. Protalix Biotherapeutics Inc Revenue Growth Rate in Lysosomal Storage Disorders Business (2018-2023)
    Figure 62. Bottom-up and Top-down Approaches for This Report
    Figure 63. Data Triangulation
    Figure 64. Key Executives Interviewed

Lysosomal storage diseases or disorders (LSDs) are rare genetic conditions that cause a buildup of toxic materials in your body's cells. People with LSDs lack certain enzymes or a substance that helps the enzyme work (enzyme activator or modifier).

According to QYResearch’s new survey, global Lysosomal Storage Disorders market is projected to reach US$ 2230.4 million in 2029, increasing from US$ 1280 million in 2022, with the CAGR of 8.2% during the period of 2023 to 2029.

Segment by Type
Enzyme Replacement Therapy
Stem Cell Therapy
Substrate Reduction Therapy
Chaperone Therapy
Others

Segment by Application
Hospital
Clinics
Stem Cell Transplant Centre
Research Institutes
Others

Industry: Medical Devices & Consumables

Published: 2023-09-03

Pages: 94 Pages

Report ld: 1502062

Request Sample

Pre-Order Enquiry

CHOOSE LICENSE TYPE

Single User License

USD 2900.00

Multi Users License

USD 4350.00

Corporate Users License

USD 5800.00

/uploads/payment/payIcon/masterCard-01.svg

/uploads/payment/payIcon/american-express-01.svg

/uploads/payment/payIcon/diners-club-01.svg

/uploads/payment/payIcon/discover-4-01.svg

Add to Cart

Buy Now

A comprehensive and in-depth analysis of current industry data on markets, competitors and suppliers.

In-depth research on key industry players and analysis of production and sales operations.

Objective forecasts of future trends in the industry.

Speak To Our Analyst >>

WHAT QYRESEARCH OFFER?